Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1994 1
1995 1
1996 4
1997 3
1998 9
1999 8
2000 11
2001 9
2002 9
2003 12
2004 7
2005 3
2007 2
2008 4
2009 2
2010 1
2014 3
2016 1
2017 2
2018 1
2020 1
2022 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.
Blum KA, Supko JG, Maris MB, Flinn IW, Goy A, Younes A, Bobba S, Senderowicz AM, Efuni S, Rippley R, Colak G, Trojer P, Abramson JS. Blum KA, et al. Among authors: senderowicz am. Cancer Res Commun. 2022 Aug 11;2(8):795-805. doi: 10.1158/2767-9764.CRC-22-0060. eCollection 2022 Aug. Cancer Res Commun. 2022. PMID: 36923307 Free PMC article. Clinical Trial.
Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target.
Sausville EA, Zaharevitz D, Gussio R, Meijer L, Louarn-Leost M, Kunick C, Schultz R, Lahusen T, Headlee D, Stinson S, Arbuck SG, Senderowicz A. Sausville EA, et al. Among authors: senderowicz a. Pharmacol Ther. 1999 May-Jun;82(2-3):285-92. doi: 10.1016/s0163-7258(98)00062-x. Pharmacol Ther. 1999. PMID: 10454206 Review.
Histone acetylation and the cell-cycle in cancer.
Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG. Wang C, et al. Among authors: senderowicz am. Front Biosci. 2001 Apr 1;6:D610-29. doi: 10.2741/1wang1. Front Biosci. 2001. PMID: 11282573 Review.
A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
Figg WD, Monga M, Headlee D, Shah A, Chau CH, Peer C, Messman R, Elsayed YA, Murgo AJ, Melillo G, Ryan QC, Kalnitskiy M, Senderowicz AM, Hollingshead M, Arbuck SG, Sausville EA. Figg WD, et al. Among authors: senderowicz am. Cancer Chemother Pharmacol. 2014 Nov;74(5):955-67. doi: 10.1007/s00280-014-2569-7. Epub 2014 Sep 3. Cancer Chemother Pharmacol. 2014. PMID: 25183650 Free PMC article. Clinical Trial.
A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.
Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, Rha SY, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T. Voss MH, et al. Among authors: senderowicz a. Ann Oncol. 2017 Nov 1;28(11):2754-2760. doi: 10.1093/annonc/mdx493. Ann Oncol. 2017. PMID: 28950297 Free article. Clinical Trial.
94 results